Clinical development of insulin-like growth factor receptor—1 (IGF-1R) inhibitors: At the crossroad?

Por Gombos, Andrea, Metzger-Filho, Otto, Dal Lago, Lissandra, Awada-Hussein, Ahmad
Publicado em 2012

Case Report: Mammary and rectal metastases from an ovarian cancer: report of two cases and review of literature

Por Amzerin, Mounia, Garcia, Camilo, Stanciu, Claudia, Veys, Isabelle, Awada, Ahmad, Errihani, Hassan, Gombos, Andrea
Publicado no F1000Res (2014)

IGF-1R targeting increases the antitumor effects of DNA damaging agents in SCLC model: an opportunity to increase the efficacy of standard therapy

Por Ferté, Charles, Loriot, Yohann, Clémenson, Céline, Commo, Frederic, Gombos, Andrea, Bibault, Jean-Emmanuel, Fumagalli, Ingrid, Hamama, Saad, Auger, Nathalie, Lahon, Benoit, Chargari, Cyrus, Calderaro, Julien, Soria, Jean-Charles, Deutsch, Eric
Publicado em 2013

Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer

Por Ignatiadis, Michail, Zardavas, Dimitrios, Lemort, Marc, Wilke, Celine, Vanderbeeken, Marie-Catherine, D’Hondt, Veronique, De Azambuja, Evandro, Gombos, Andrea, Lebrun, Fabienne, Dal Lago, Lissandra, Bustin, Fanny, Maetens, Marion, Ameye, Lieveke, Veys, Isabelle, Michiels, Stefan, Paesmans, Marianne, Larsimont, Denis, Sotiriou, Christos, Nogaret, Jean-Marie, Piccart, Martine, Awada, Ahmad
Publicado no PLoS One (2016)